Simon Dagenais

机构：Pfizer (United States) · ORCID：0000-0003-3062-9312

发表论文 151 篇 · 总被引 8401 次 · h-index 41

代表论文

Guideline summary review: an evidence-based clinical guideline for the diagnosis and treatment of low back pain (2020 · The Spine Journal · 被引 248)
Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design (2021 · Clinical Pharmacology & Therapeutics · 被引 150)
Research Agenda for the Prevention of Pain and Its Impact: Report of the Work Group on the Prevention of Acute and Chronic Pain of the Federal Pain Research Strategy (2018 · Journal of Pain · 被引 93)
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective (2023 · Clinical Pharmacology & Therapeutics · 被引 39)
A systematic review comparing the costs of chiropractic care to other interventions for spine pain in the United States (2015 · BMC Health Services Research · 被引 32)
Impact of treatment with liposomal bupivacaine on hospital costs, length of stay, and discharge status in patients undergoing total knee arthroplasty at high-use institutions (2018 · Journal of Medical Economics · 被引 20)